All In Biotech

Drug Trial Radar · NCT03643276

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Jul 15, 2018

Primary completion

Jul 14, 2028

Study completion Jul 14, 2028

Sponsor

Lead sponsor
Martin SchrappeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany)
First posted
Aug 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction of more accurate methods of assessing therapy response ("minimal residual disease \[MRD\] tests") has provided new insights into very different mechanisms of action, including factors influenced by host factors; this has had practical clinical consequences for the use of more individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in this age group. However, the own and international study data show that the therapy toxicity of the contemporary chemotherapy concepts has become unacceptably high, in particular with respect to those intensified therapies used for the treatment of patients at high risk of ALL relapse. The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will not only adapt the risk stratification to new prognostic markers using more comprehensive diagnostics, but above all, qualitatively reorient the therapy. The most important consequence will be that this study is testing immunotherapy with the bispecific antibody blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in precursor B-cell ALL (pB-ALL) patients with detectable chemotherapy resistance and at high risk of relapse. With the aim to complement the effects of the conventional chemotherapy, Blinatumomab is in addition tested in the large group of pB-ALL patients at intermediate relapse risk with seemingly unremarkable leukemia, but who account for a large proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the aim to overcome intrinsic chemotherapy resistance of the ALL cells. In patients with T-lineage ALL, who have particularly poor chances for cure after relapse, the established consolidation chemotherapy has proved to be particularly effective. This chemotherapy phase is therefore tested in a longer and more intensive form in such T-ALL patients with intermediate or slow early treatment response with the aim to reduce the relapses rate in this subgroup.

Conditions

  • Acute Lymphoblastic Leukemia, Pediatric

Interventions

  • BlinatumomabDrug

    Experimental therapy in randomizations R-HR and R-MR

  • BortezomibDrug

    Experimental therapy in randomization R-eHR

  • CyclophosphamideDrug

    Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

  • CytarabineDrug

    Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk

  • DaunorubicinDrug

    Part of standard chemotherapy

  • MyocetDrug

    Part of intensification block Myocet-FLA for patients with very high relapse risk

  • DexamethasoneDrug

    Part of standard chemotherapy

  • DoxorubicinDrug

    Part of standard chemotherapy

  • EtoposideDrug

    Part of standard chemotherapy

  • Fludarabine PhosphateDrug

    Part of intensification block Myocet-FLA for patients with very high relapse risk

  • IfosfamideDrug

    Part of standard chemotherapy

  • 6-MercaptopurineDrug

    Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T

  • MethotrexateDrug

    Part of standard chemotherapy

  • PegaspargaseDrug

    Part of standard chemotherapy

  • PrednisoloneDrug

    Part of standard chemotherapy

  • TioguaninDrug

    Part of standard chemotherapy

  • VincristineDrug

    Part of standard chemotherapy

  • VindesineDrug

    Part of standard chemotherapy

  • ErwinaseDrug

    Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: Assessed up to 120 months from start of study
  2. Disease-free survivalTime frame: Assessed up to 120 months from start of study

Locations

115 sites in 8 countries. Site status is shown where the registry gives one.

  • Sydney Children's Hospital

    Sydney, Australia · Recruiting

  • The Children's Hospital at Westmead

    Westmead, Australia · Recruiting

  • Univ.Klinik für Kinder- und Jugendheilkunde Graz

    Graz, Austria · Recruiting

  • Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck

    Innsbruck, Austria · Recruiting

  • Kepler Universitätsklinikum

    Linz, Austria · Recruiting

  • LKH Salzburg

    Salzburg, Austria · Recruiting

  • St. Anna Kinderspital

    Vienna, Austria · Recruiting

  • University Hospital Brno

    Brno, Czechia · Recruiting

  • Regional Hospital České Budějovice

    České Budějovice, Czechia · Recruiting

  • University Hospital Hradec Králové

    Hradec Králové, Czechia · Recruiting

  • University Hospital Olomouc

    Olomouc, Czechia · Recruiting

  • University Hospital Ostrava-Poruba

    Ostrava-Poruba, Czechia · Recruiting

  • University Hospital Plzeň

    Pilsen, Czechia · Recruiting

  • University Hospital Motol

    Prague, Czechia · Recruiting

  • Masaryk´s Hospital Ústí nad Labem

    Ústí nad Labem, Czechia · Recruiting

  • Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie

    Aachen, Germany · Recruiting

  • I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie

    Augsburg, Germany · Recruiting

  • Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie

    Berlin, Germany · Recruiting

  • Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie

    Berlin, Germany · Recruiting

  • Städtisches Krankenhaus, Kinderklinik

    Braunschweig, Germany · Recruiting

  • Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie

    Chemnitz, Germany · Recruiting

  • Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl

    Cologne, Germany · Recruiting

  • Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station

    Cologne, Germany · Recruiting

  • Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie

    Cottbus, Germany · Recruiting

  • Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke

    Datteln, Germany · Recruiting

  • Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin

    Dortmund, Germany · Recruiting

  • Universitatsklinikum Carl Gustav Carus

    Dresden, Germany · Recruiting

  • Universitätsklinik

    Düsseldorf, Germany · Recruiting

  • Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde

    Erfurt, Germany · Recruiting

  • Universitaets - Kinderklinik

    Erlangen, Germany · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Klinikum der J.W. Goethe Universitaet

    Frankfurt, Germany · Recruiting

  • Universitaetskinderklinik - Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie

    Giessen, Germany · Recruiting

  • Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie

    Göttingen, Germany · Recruiting

  • Klinik und Poliklinik für Kinder und Jugendmedizin, Allgemeine Pädiatrie mit Poliklinik/Pädiatrische Onkologie und Hämatologie

    Greifswald, Germany · Recruiting

  • Medizinische Hochschule Hannover, Zentrum Kinderheilkunde u. Jugendmedizin

    Hanover, Germany · Recruiting

  • Universitäts-Kinderklinik, Päd. Onkologie, Hämatologie, und Immunologie

    Heidelberg, Germany · Recruiting

  • Klinikum Heilbronn GmbH, Klinik für Kinderheilkunde und Jugendmedizin/Perinatalzentrum

    Heilbronn, Germany · Recruiting

  • Gemeinschaftskrankenhaus Herdecke, Kinderabteilung

    Herdecke, Germany · Recruiting

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.